Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Non-small Cell Lung Cancer Age: Adult |
Dose: Oral – 45 mg Frequency: once daily Note: Indicated for first-line treatment of patients with metastatic non-small lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Continue until disease progression or unacceptable toxicity occurs. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Osteoporosis, osteomalacia, rickets, tetany, parathyroid disease, pregnancy and lactation, osteogenesis, tooth formation, anti-seizure medication therapy, or chronic renal failure |
Dose: Tablet – 500 mg Calcium and 200 international units Vitamin D3 Frequency: 1 tablet twice daily or 2 tablets once daily Note: by mouth (oral). Best taken with or just after a meal to improve absorption. |
|
Indication: Osteoporosis, osteomalacia, rickets, tetany, parathyroid disease, pregnancy and lactation, osteogenesis, tooth formation, anti-seizure medication therapy, or chronic renal failure |
Dose: Tablet – 500 mg Calcium and 400 international units Vitamin D3 Frequency: 1 tablet twice daily Note: by mouth (oral). Best taken with or just after a meal to improve absorption. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild or moderate (Creatinine Clearance 30-89 mL/min estimated by Cockcroft-Gault equation) |
Dose: No dosage adjustment necessary Note: No dosage adjustment necessary |
|
Condition: Renal impairment Severe (Creatinine Clearance less than 30 mL/min) |
Dose: Recommended dose not established Note: Recommended dose not established |
Administration
- Take with or without food
- Take at same time daily
Side Effect
- Diarrhea (87%)
- Rash (69%)
- Paronychia (64%)
- Stomatitis (45%)
- Anemia (44%)
- Hypoalbuminemia (44%)
- Lymphopenia (42%)
- Increased ALT (40%)
- Hyperglycemia (36%)
- Increased AST (35%)
- Hypocalcemia (33%)
- Decreased appetite (31%)
- Dry skin (30%)
- Hypokalemia (29%)
- Decreased weight (26%)
- Hyponatremia (26%)
- Increased creatinine (24%)
- Alopecia (23%)
- Increased alkaline phosphatase (22%)
- Hypomagnesemia (22%)
- Pruritus (21%)
- Cough (21%)
- Nasal mucosal disorder (19%)
- Conjunctivitis (19%)
- Nausea (19%)
- Hyperbilirubinemia (16%)
- Palmar-plantar erythrodysesthesia syndrome (15%)
- Pain in extremity (14%)
- Dyspnea (13%)
- Constipation (13%)
- Asthenia (13%)
- Mouth ulceration (12%)
- Musculoskeletal pain (12%)
- Upper respiratory tract infection (URTI) (12%)
- Dermatitis (11%)
- Insomnia (11%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.